ESMO Congress

Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.

Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.

Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.

Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.

Experts in the gynecologic cancer landscape highlight their most anticipated presentations ahead of the 2025 ESMO Congress.

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

OncLive social media polls reveal which lung cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.

Dual HER2 blockade with trastuzumab plus pertuzumab may serve as an effective option for hormone receptor–positive, HER2-positive metastatic breast cancer.

Targeted treatment as determined by mutational status was associated with ORR and PFS benefits in pretreated patients with metastatic solid tumors.

The addition of fecal microbiota transplantation to pembrolizumab and axitinib raised the efficacy of the combination in metastatic renal cell carcinoma.

Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.

Adjuvant pembrolizumab generated a DFS benefit vs observation in patients with high-risk muscle-invasive bladder cancer after radical surgery.

Patients with HR-positive breast cancer who conceived during a break from endocrine therapy found breastfeeding feasible and safe.

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

Elacestrant plus abemaciclib demonstrated clinical activity and manageable safety in pretreated ER+/HER2– metastatic breast cancer.

Lenvatinib plus pembrolizumab led to tumor responses regardless of mismatch repair–proficient status, histology, and prior adjuvant therapy.

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

Neoadjuvant chemotherapy improved organ preservation in nasal and paranasal sinus squamous cell carcinoma.

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.